Shuttle Pharmaceuticals (NASDAQ:SHPH – Get Free Report) and Cassava Sciences (NASDAQ:FLNA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Analyst Ratings
This is a summary of current ratings and target prices for Shuttle Pharmaceuticals and Cassava Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shuttle Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Cassava Sciences | 1 | 0 | 1 | 0 | 2.00 |
Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given Cassava Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Shuttle Pharmaceuticals.
Risk & Volatility
Profitability
This table compares Shuttle Pharmaceuticals and Cassava Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shuttle Pharmaceuticals | N/A | -408.34% | -138.15% |
| Cassava Sciences | N/A | -53.90% | -34.20% |
Valuation & Earnings
This table compares Shuttle Pharmaceuticals and Cassava Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shuttle Pharmaceuticals | N/A | N/A | -$11.72 million | ($4.77) | -0.10 |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.82 |
Cassava Sciences is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Cassava Sciences beats Shuttle Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
